openPR Logo
Press release

Investigation announced for Long-Term Investors in shares of MacroGenics, Inc. (NASDAQ: MGNX)

06-14-2021 09:55 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation on behalf of current long term investors in MacroGenics, Inc. (NASDAQ: MGNX) shares.

An investigation on behalf of current long term investors in MacroGenics, Inc. (NASDAQ: MGNX) shares.

An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of MacroGenics, Inc.

Investors who are current long term investors in MacroGenics, Inc. (NASDAQ: MGNX) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for current long term investors in NASDAQ: MGNX stocks follows a lawsuit filed against MacroGenics, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: MGNX stocks, concerns whether certain MacroGenics directors are liable in connection with the allegations made in that lawsuit.

According to that complaint filed in the U.S. District Court for the District of Maryland the plaintiff alleges that, the defendants concealed material information and/or failed to disclose that the Company had conducted the progression-free survival (“PFS”) and first interim overall survival (“OS”) analyses for the SOPHIA trial by no later than October 10, 2018, that the October 2018 PFS analysis showed a 0.9 month improvement in PFS, and that the October 2018 OS interim analysis did not produce a statistically significant result and the interim OS Kaplan-Meier curves (a non-parametric statistic used to estimate the survival function from lifetime data) crossed in several spots (thereby violating the constant hazard assumption) and separated late.

Those who purchased shares of MacroGenics, Inc. (NASDAQ: MGNX) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Long-Term Investors in shares of MacroGenics, Inc. (NASDAQ: MGNX) here

News-ID: 2305003 • Views:

More Releases from Shareholders Foundation

Lawsuit filed for certain Investors who lost money with shares of Global Cord Blood Corporation (OTC: CORBF)
Lawsuit filed for certain Investors who lost money with shares of Global Cord Bl …
An investor, who purchased shares of Global Cord Blood Corporation (OTC: CORBF), filed a lawsuit over alleged violations of Federal Securities Laws by Global Cord Blood Corporation in connection with certain allegedly false and misleading statements. Investors who purchased shares of Global Cord Blood Corporation (OTC: CORBF) have certain options and for certain investors are short and strict deadlines running. Deadline: June 24, 2024. OTC: CORBF investors should contact the Shareholders
Lawsuit filed for Investors who lost money with shares of Autodesk, Inc. (NASDAQ: ADSK)
Lawsuit filed for Investors who lost money with shares of Autodesk, Inc. (NASDAQ …
An investor, who purchased shares of Autodesk, Inc. (NASDAQ: ADSK), filed a lawsuit over alleged violations of Federal Securities Laws by Autodesk, Inc. in connection with certain allegedly false and misleading statements. Investors who purchased shares of Autodesk, Inc. (NASDAQ: ADSK) have certain options and for certain investors are short and strict deadlines running. Deadline: June 24, 2024. NASDAQ: ADSK investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)
Investors who lost money with shares of AST SpaceMobile, Inc. (NASDAQ: ASTS) should contact the Shareholders Foundation in connection with pending lawsuit
Investors who lost money with shares of AST SpaceMobile, Inc. (NASDAQ: ASTS) sho …
An investor, who purchased shares of AST SpaceMobile, Inc. (NASDAQ: ASTS), filed a lawsuit over alleged violations of Federal Securities Laws by AST SpaceMobile, Inc. in connection with certain allegedly false and misleading statements. Investors who purchased shares of AST SpaceMobile, Inc. (NASDAQ: ASTS) have certain options and for certain investors are short and strict deadlines running. Deadline: June 17, 2024. NASDAQ: ASTS investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com
Lawsuit filed for Investors who lost money with shares of Sharecare, Inc. (NASDAQ: SHCR)
Lawsuit filed for Investors who lost money with shares of Sharecare, Inc. (NASDA …
An investor, who purchased shares of Sharecare, Inc. (NASDAQ: SHCR), filed a lawsuit over alleged violations of Federal Securities Laws by Sharecare, Inc. Investors who purchased shares of Sharecare, Inc. (NASDAQ: SHCR) have certain options and for certain investors are short and strict deadlines running. Deadline: June 18, 2024. NASDAQ: SHCR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. Atlanta, GA based Sharecare, Inc. operates as

All 5 Releases


More Releases for MacroGenics

Breast Cancer Drug Market Growing Popularity and Emerging Trends | Celldex Thera …
Global Breast Cancer Drug Market is rise gradually to an estimated value of USD 43.63 Billion by 2026 registering a CAGR of 11.1% in the forecast period of 2019-2026. This rise in market value can be attributed to the increasing awareness and concerns regarding the health of patients. The Breast Cancer Drug market report includes data on consumer perspective, comprehensive analysis, statistics, market share, corporate performance (stocks), historical analysis from 2019
Lawsuit filed for Investors in shares of MacroGenics, Inc. (NASDAQ: MGNX)
An investor, who purchased shares of MacroGenics, Inc. (NASDAQ: MGNX), filed a lawsuit over alleged violations of Federal Securities Laws by MacroGenics, Inc.. Investors who purchased shares of MacroGenics, Inc. (NASDAQ: MGNX) have certain options and for certain investors are short and strict deadlines running. Deadline: November 12, 2019. NASDAQ: MGNX investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. Rockvillem MD based MacroGenics, Inc., a biopharmaceutical
Ewing Sarcoma Therapeutics - Pipeline Analysis Celgene, Novartis, Pfizer, MacroG …
Ewing sarcoma pipeline comprises approximately 29 drug candidates in different stages of development. Ewing sarcoma is a condition in which formation of cancer or tumor takes place in bones and soft tissues. The symptoms associated with Ewing sarcoma include pain as well as swelling in the chest, back, legs, pelvis and arms, lumps in arms, bone fracture, weight loss, loss of appetite, fatigue, malaise, etc. Download free report Sample at: https://www.psmarketresearch.com/market-analysis/ewing-sarcoma-therapeutics-pipeline-analysis/report-sample *Major companies
Global Cancer Stem Cells Market Size, Status and Forecast 2018-2025 | Merck Kgaa …
Researchmoz added Most up-to-date research on "Global Cancer Stem Cells Market Size, Status and Forecast 2018-2025" to its huge collection of research reports. This report focuses on the global Cancer Stem Cells status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Cancer Stem Cells development in United States, Europe and China. Cancer stem cells (CSCs) are cancer cells (found within tumors or hematological cancers)
Global ANTI-CD19 ANTIBODY Market 2018 Key Players: CRISPR Therapeutics, Juno The …
ANTI-CD19 ANTIBODY Market: WiseGuyReports.com adds “ANTI-CD19 ANTIBODY Market 2018 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting” reports to its database. Executive Summary The comprehensive list of anti-CD19 antibody that are marketed for different indications and the products that are in development. The main objective of this report is to provide a comprehensive secondary research and market analysis of anti-CD19 antibody pipeline products that are in Phase 3, Phase 2, Phase 1,
Macrogenics - Cancer Drugs Clinical Pipeline Insight
“Macrogenics - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Macrogenics. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “11” cancer drugs in clinical pipeline and majority of them are in phase-I. The report includes all the relevant information with respect to development of cancer drugs in